Evidence map›Paper›PMID 25181527›Full record

ArticlePloS one2014

A protein L-based immunodiagnostic approach utilizing time-resolved Förster resonance energy transfer.

Satu Hepojoki, Visa Nurmi, Antti Vaheri, Klaus Hedman, Olli Vapalahti, Jussi Hepojoki

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Satu HepojokiDepartment of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Visa NurmiDepartment of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Antti VaheriDepartment of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland; Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Laboratory Services, HUSLAB, Helsinki, Finland.
Klaus HedmanDepartment of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland; Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Laboratory Services, HUSLAB, Helsinki, Finland.
Olli VapalahtiDepartment of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland; Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Laboratory Services, HUSLAB, Helsinki, Finland; Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Jussi HepojokiDepartment of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FIHospital District of Helsinki and Uusimaa · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chelated lanthanides such as europium (Eu) have uniquely long fluorescence emission half-lives permitting their use in time-resolved fluorescence (TRF) assays. In Förster resonance energy transfer (FRET) a donor fluorophore transfers its emission energy to an acceptor fluorophore if in sufficiently close proximity. The use of time-resolved (TR) FRET minimizes the autofluorescence of molecules present in biological samples. In this report, we describe a homogenous immunoassay prototype utilizing TR-FRET for detection of antibodies in solution. The assay is based on labeled protein L, a bacterial protein that binds to immunoglobulin (Ig) light chain, and labeled antigen, which upon association with the same Ig molecule produce a TR-FRET active complex. We show that the approach is functional and can be utilized for both mono- and polyvalent antigens. We also compare the assay performance to that of another homogenous TR-FRET immunoassay reported earlier. This novel assay may have wide utility in infectious disease point-of-care diagnostics.

Indexed as

Antibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial ProteinsCarbocyaninesDNA-Binding ProteinsEnzyme-Linked Immunosorbent AssayEuropiumFluorescence Resonance Energy TransferHumansImmunoassayImmunoglobulin Fab FragmentsImmunoglobulin GImmunologic TestsLimit of DetectionProtein BindingAlexa Fluor 647Antibodies, BacterialAntibodies, MonoclonalAntigens, BacterialBacterial ProteinsCarbocyaninesDNA-Binding ProteinsEuropiumImmunoglobulin Fab FragmentsImmunoglobulin GL-protein, Peptococcus magnus

Identifiers

PMID25181527
PMCPMC4152265
OpenAlexW2040923823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.